It's still a good dividend sto_老虎社区_美港股上老虎

SheperdBoy
2021-09-02

It's still a good dividend stock nevertheless. Why not stick all kinds of fast food with the heart risk label stickers on all the wrappers boxes?

Why AbbVie Is Down More Than 7% Wednesday

The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions

Why AbbVie Is Down More Than 7% Wednesday

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":812273894,"tweetId":"812273894","gmtCreate":1630592397118,"gmtModify":1631891938674,"author":{"id":3586776007027881,"idStr":"3586776007027881","authorId":3586776007027881,"authorIdStr":"3586776007027881","name":"SheperdBoy","avatar":"https://static.tigerbbs.com/a7fe7335d9e335fad57e8874b3f8ce39","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>It's still a good dividend stock nevertheless. Why not stick&nbsp;all kinds of fast food with the heart risk label stickers on all the wrappers boxes?</p></body></html>","htmlText":"<html><head></head><body><p>It's still a good dividend stock nevertheless. Why not stick&nbsp;all kinds of fast food with the heart risk label stickers on all the wrappers boxes?</p></body></html>","text":"It's still a good dividend stock nevertheless. Why not stick all kinds of fast food with the heart risk label stickers on all the wrappers boxes?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/812273894","repostId":1191563735,"repostType":2,"repost":{"id":"1191563735","pubTimestamp":1630542500,"share":"https://www.laohu8.com/m/news/1191563735?lang=&edition=full","pubTime":"2021-09-02 08:28","market":"us","language":"en","title":"Why AbbVie Is Down More Than 7% Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191563735","media":"Motley Fool","summary":"The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions ","content":"<blockquote>\n The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers.\n</blockquote>\n<p><b>What happened</b></p>\n<p>Shares of drugmaker<b>AbbVie</b>(NYSE:ABBV)are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.</p>\n<p><b>So what</b></p>\n<p>As part of its routine reviews of clinical trial data, the FDA announced Wednesday that all Janus kinase (JAK) inhibitors approved for use as arthritis treatments in the United States are now to be sold with a label cautioning their users that such drugs raise the risk of serious heart-related events, cancer, blood clots, and even death. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs.</p>\n<p>Blame<b>Pfizer</b>(NYSE:PFE), however. The FDA's decision was rooted in data regarding Pfizer's arthritis medicine Xeljanz. The two drugs in question are built around the same JAK-inhibiting approach, and in its later-stage testing it was shown to increase the risk of blood clots and related heart problems.</p>\n<p><b>Now what</b></p>\n<p>The knee-jerk reaction is understandable. While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of thepharmaceuticalfranchises hoped to help replace the loss of sales linked to the expiration of Humira's patents.</p>\n<p>As it stands right now though, Rinvoq accounts for less than 3% of AbbVie's revenue, and its potential was still unclear. The pharmaceutical giant also still has more than two dozen drugs in its portfolio -- many of which are already bigger franchises than Rinvoq -- and even more in the research and development pipeline. There's also nothing to firmly suggest arthritic patients will abandon or avoid the drug simply because of the label warning. Once investors work through the initial shock of Wednesday's news, the sell-off could readily become a buying opportunity for investors already eyeing the stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AbbVie Is Down More Than 7% Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AbbVie Is Down More Than 7% Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers.\n\nWhat happened\nShares of drugmakerAbbVie(NYSE:ABBV)are off by 7.8% in...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191563735","content_text":"The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers.\n\nWhat happened\nShares of drugmakerAbbVie(NYSE:ABBV)are off by 7.8% in Wednesday afternoon's trading session following a decision from the Food and Drug Administration to require a heart-risk warning on the label of its arthritis treatment Rinvoq.\nSo what\nAs part of its routine reviews of clinical trial data, the FDA announced Wednesday that all Janus kinase (JAK) inhibitors approved for use as arthritis treatments in the United States are now to be sold with a label cautioning their users that such drugs raise the risk of serious heart-related events, cancer, blood clots, and even death. AbbVie's Rinvoq is one of these JAK-inhibiting prescription drugs.\nBlamePfizer(NYSE:PFE), however. The FDA's decision was rooted in data regarding Pfizer's arthritis medicine Xeljanz. The two drugs in question are built around the same JAK-inhibiting approach, and in its later-stage testing it was shown to increase the risk of blood clots and related heart problems.\nNow what\nThe knee-jerk reaction is understandable. While AbbVie is best known for its arthritis, plaque psoriasis, and Crohn's disease treatment Humira, Rinvoq was one of thepharmaceuticalfranchises hoped to help replace the loss of sales linked to the expiration of Humira's patents.\nAs it stands right now though, Rinvoq accounts for less than 3% of AbbVie's revenue, and its potential was still unclear. The pharmaceutical giant also still has more than two dozen drugs in its portfolio -- many of which are already bigger franchises than Rinvoq -- and even more in the research and development pipeline. There's also nothing to firmly suggest arthritic patients will abandon or avoid the drug simply because of the label warning. Once investors work through the initial shock of Wednesday's news, the sell-off could readily become a buying opportunity for investors already eyeing the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":120,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}